Mythic Therapeutics Receives FDA Fast Track Designation for MYTX-011 for Patients with Non-Small Cell Lung Cancer (NSCLC) with cMET Overexpression
Mythic Therapeutics , a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Mythic’s investigational cMET-targeting ADC, MYTX-011, for the treatment of patients with non-small cell lung cancer (NSCLC) with cMET overexpression.